Skip to content

PHAROVENT

Active Risk: not assessed Private limited companyfounded 2013active for 13 yearsStrijpstraat 35, 9750 KruisemKBO/BCE: BE 0536.820.170 #4 company by total assets in Kruisem, Accommodation and food service sector

Timeline

27 events since 2013

The 2026 accounts are due by 30-04-2027.

2026
Annual accounts 2025 filed PDFabbreviated format · 31 days before the deadline
2025
Back to profit net €52,983 The net result is €52,983, after one loss-making year.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0536820170
Annual accounts 2024 filed PDFabbreviated format · 15 days before the deadline
2024
Annual accounts 2023 filed PDFabbreviated format · 1 day before the deadline
2023
(director) and (director) change roles“1. Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van…” (deed in Dutch) · 300 shares · General meeting of 21-12-20237 points ▸
  • General meeting, 21-12-2023
  • Purpose change, “1. Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van diensten,adviezen,de uitvoering,de studie en organisatie…” (deed in Dutch)
  • 300 shares
  • Director resignation, (manager)
  • Director appointment, (director (not named in the articles))
  • Director resignation, (manager)
  • Director appointment, (director (not named in the articles))
  • The deed holds 8 more points.

Open the deed in the Belgian Official Gazette

Back to profit net €104,523 The net result is €104,523, after one loss-making year.
Annual accounts 2022 filed PDFabbreviated format · 2 days before the deadline
2022
Weakest financial year net -€55,630 The net result drops to -€55,630, the lowest from 2014 to 2025. It recovers the following year.
Annual accounts 2021 filed PDFabbreviated format · 31 days before the deadline
2021
Annual accounts 2020 filed PDFabbreviated format · 32 days before the deadline
2020
Annual accounts 2019 filed PDFabbreviated format · 36 days before the deadline
2019
Annual accounts 2018 filed PDFabbreviated format · 32 days before the deadline
2018
Highest result from 2014 to 2025 net €137,721 ▲4.1% The operating result of €258,900 and the net result of €137,721 are both a record.
Equity above €500,000 equity €559,191 ▲32.7% With a profit in every financial year since 2014, equity grows to €559,191.
Annual accounts 2017 filed PDFabbreviated format · 38 days before the deadline
2017
Annual accounts 2016 filed PDFabbreviated format · 54 days before the deadline
2016
General meeting of 03-11-20161 point ▸
  • General meeting, 03-11-2016
  • The deed holds 3 more points.

Open the deed in the Belgian Official Gazette

Company renamed from TD PHARMA to PHAROVENT BVBA“Assistentie op het gebied van management en het voeren van consultingactiviteiten.Het verlenen van…” (deed in Dutch) · General meeting of 09-09-20163 points ▸
  • Power of attorney,
  • General meeting, 09-09-2016
  • Name change, PHAROVENT BVBA
  • The deed holds 3 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2015 filed PDFabbreviated format · 37 days before the deadline
appointed as managerGeneral meeting of 01-12-20152 points ▸
  • General meeting, 01-12-2015
  • Director appointment, (manager)

Open the deed in the Belgian Official Gazette

2015
Equity above €200,000 equity €216,127 ▲52.7% With a profit in every financial year since 2014, equity grows to €216,127.
Annual accounts 2014 filed PDFabbreviated format · 36 days before the deadline
2014
Merger: TD Pharma takes over Isem Pharma“Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van diensten…” (deed in Dutch) · The company holds all the shares of Isem Pharma · Share cancellation: Isem Pharma · General meeting of 30-06-20146 points ▸
  • General meeting, 30-06-2014
  • The company holds all the shares of Isem Pharma
  • Share cancellation, Isem Pharma
  • Capital, €100,000
  • Capital, €100,000, 100 shares
  • Director discharge, (manager)
  • The deed holds 7 more points.

Open the deed in the Belgian Official Gazette

Merger proposal: BVBA TD PHARMA takes over BVBA ISEM PHARMAThe company holds all the shares of BVBA ISEM PHARMA4 points ▸
  • The company holds all the shares of BVBA ISEM PHARMA
  • Capital, €100,000, 100 shares
  • Capital, €57,500, 100 shares
  • Accounting effect, 01-01-2014
  • The deed holds 5 more points.

Open the deed in the Belgian Official Gazette

2013
First establishment Strijpstraat 35, Kruisem
IncorporationFounding capital of €100,000, 100 shares · Founded by (comparant) · Capital of €100,000, 100 shares · published on 30-07-20133 points ▸
  • Capital, €100,000, 100 shares
  • Founder, (comparant)
  • Founding capital, €100,000, 100 shares
  • The deed holds 5 more points.

Open the deed in the Belgian Official Gazette

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 19 July 2013, PHAROVENT was incorporated by one private individual, with a starting capital of €100,000.12 Isem Pharma was merged into the company in 2014.3 The name was changed to PHAROVENT BVBA in 2016 and to PHAROVENT in 2016.45 Today the board has 2 members.6 Total assets went from €2.1m in 2019 to €2.8m in 2025.7

  1. 1KBO register
  2. 2Belgian Official Gazette, 30-07-2013
  3. 3Belgian Official Gazette, 23-07-2014
  4. 4Belgian Official Gazette, 22-09-2016
  5. 5Belgian Official Gazette, 21-11-2016
  6. 6National Bank, annual accounts 2025
  7. 7National Bank, annual accounts 2019 and 2025

Mentions of companies taken over

ISEM PHARMA, the company PHAROVENT took over in the merger of 30-06-2014, is named in 8 deeds.
Show the 8 deeds

Next steps